Citations

Clear

1422 citation(s) found for "White, JB".

Fecal Metabolomic Signatures in Colorectal Adenoma Patients Are Associated with Gut Microbiota and Early Events of Colorectal Cancer Pathogenesis
Kim, Minsuk , Vogtmann, Emily , Ahlquist, David A. , Devens, Mary E., Taylor, William R. , White, Bryan A. , Hale, Vanessa L. , Sung, Jaeyun , Chia, Nicholas , Sung, Jaeyun , Kim, Minsuk , Kisiel, John B. , Taylor, William R., Chia, Nicholas , Sinha, Rashmi R. , Chen, Jun

Mayo Clinic

mBio | February 17, 2020 | Volume: 11 | Issue: 1 | Pages: No page available

10.1128/mbio.03186-19 | PMID 32071266 Get It

Colorectal adenomas are precursors of CRC. Recently, the gut microbiota, i.e., the collection of microbes residing in our gut, has been recognized as a key player in CRC development. There have been a number of gut microbiota profiling studies for colorectal adenoma and CRC; however, fewer studies have considered the gut metabolome, which serves as the chemical interface between the host and gut microbiota. Here, we conducted a gut metabolome profiling study of colorectal adenoma and CRC and analyzed the metabolomic profiles together with paired microbiota composition profiles. We found several chemical signatures of colorectal adenoma that were associated with some gut microbes and potentially indicative of future CRC. This study highlights potential early-driver metabolites in CRC pathogenesis and guides further targeted experiments and thus provides an important stepping stone toward developing better CRC prevention strategies.
Mendelian Randomization of Circulating Polyunsaturated Fatty Acids and Colorectal Cancer Risk
Khankari, Nikhil K. , Banbury, Barbara L. , Borges, Maria Carolina , Haycock, Philip , Arndt, Volker , Berndt, Sonja I. , Brenner, Hermann , Casey, Graham , Chang‐Claude, Jenny , Conti, David V. , English, Dallas R. , Figueiredo, Jane C. , Giovannucci, Edward L. , Gunter, Marc J. , Hampe, Jochen , Hoffmeister, Michael , Joshi, Amit D. , Lemire, Mathieu , Li, Li , Lindblom, Annika , Martín, Vicente , Moreno, Vı́ctor , Offit, Kenneth, Rennert, Gad , Schafmayer, Clemens , Schmit, Stephanie L. , Slattery, Martha L. , Thibodeau, Stephen N. , Weinstein, Stephanie J. , Win, Aung Ko , Woods, Michael O. , Wu, Anna H. , Murff, Harvey J. , Gruber, Stephen B. , Peters, Ulrike , Brenner, Hermann , Borges, Maria C , Arndt, Volker , Brenner, Hermann , Chang-Claude, Jenny , English, Dallas R , Giles, Graham G , Hoffmeister, Michael , Martín, Vicente , Moreno, Victor , Pharoah, Paul D P , Rennert, Gad , Sakoda, Lori C , Slattery, Martha L , Weinstein, Stephanie J , Win, Aung K , Wolk, Alicja , Denny, Joshua C , Gunter, Marc J , Haycock, Philip , Brenner, Hermann , Hampe, Jochen , Conti, David V , Lindblom, Annika , Albanes, Demetrius , Bezieau, Stéphane , Campbell, Peter T. , Chan, Andrew T. , Cotterchio, Michelle , Giles, Graham G. , Hopper, John L. , Jenkins, Mark A. , Marchand, Loı̈c Le , Li, Christopher I , Newcomb, Polly A. , Pharoah, Paul D.P. , Sakoda, Lori C. , Song, Mingyang , Ulrich, Cornelia M. , White, Emily , Wolk, Alicja , Cai, Qiuyin , Denny, Joshua C. , Edwards, Todd L. , Zheng, Wei

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 12, 2020 | Volume: 29 | Issue: 4 | Pages: 860-870

10.1158/1055-9965.epi-19-0891 | PMID 32051193 Get It

Abstract Background: Results from epidemiologic studies examining polyunsaturated fatty acids (PUFA) and colorectal cancer risk are inconsistent. Mendelian randomization may strengthen causal inference from observational studies. Given their shared metabolic pathway, examining the combined effects of aspirin/NSAID use with PUFAs could help elucidate an association between PUFAs and colorectal cancer risk. Methods: Information was leveraged from genome-wide association studies (GWAS) regarding PUFA-associated SNPs to create weighted genetic scores (wGS) representing genetically predicted circulating blood PUFAs for 11,016 non-Hispanic white colorectal cancer cases and 13,732 controls in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). Associations per SD increase in the wGS were estimated using unconditional logistic regression. Interactions between PUFA wGSs and aspirin/NSAID use on colorectal cancer risk were also examined. Results: Modest colorectal cancer risk reductions were observed per SD increase in circulating linoleic acid [ORLA = 0.96; 95% confidence interval (CI) = 0.93–0.98; P = 5.2 × 10−4] and α-linolenic acid (ORALA = 0.95; 95% CI = 0.92–0.97; P = 5.4 × 10−5), whereas modest increased risks were observed for arachidonic (ORAA = 1.06; 95% CI = 1.03–1.08; P = 3.3 × 10−5), eicosapentaenoic (OREPA = 1.04; 95% CI = 1.01–1.07; P = 2.5 × 10−3), and docosapentaenoic acids (ORDPA = 1.03; 95% CI = 1.01–1.06; P = 1.2 × 10−2). Each of these effects was stronger among aspirin/NSAID nonusers in the stratified analyses. Conclusions: Our study suggests that higher circulating shorter-chain PUFAs (i.e., LA and ALA) were associated with reduced colorectal cancer risk, whereas longer-chain PUFAs (i.e., AA, EPA, and DPA) were associated with an increased colorectal cancer risk. Impact: The interaction of PUFAs with aspirin/NSAID use indicates a shared colorectal cancer inflammatory pathway. Future research should continue to improve PUFA genetic instruments to elucidate the independent effects of PUFAs on colorectal cancer.
Opioid Use in Fibromyalgia Continues Despite Guidelines That Do Not Support Its Efficacy or Risk
Bruce, Barbara K. , Allman, Madeleine , Rivera, Fernando A. , Abril, Andy , Gehin, Jessica M. , Oliphant, Loretta M., Nordan, Lisa, White, Launia J. , Martinez, Dayana, Niazi, Shehzad K. , Nordan, Lisa M, Oliphant, Loretta Marie

Mayo Clinic

JCR: Journal of Clinical Rheumatology | February 10, 2020 | Volume: 27 | Issue: 5 | Pages: 187-193

10.1097/rhu.0000000000001273 | PMID 32040055 Get It

Background/Objective The aim of this cross-sectional study is to determine the prevalence of opioid use in a large sample of fibromyalgia (FM) patients and examine the factors associated with opioid prescription/use despite multiple clinical guidelines that do not recommend opioid use in this population. Methods Data were collected from a convenience sample of 698 patients admitted from August 2017 to May 2019 into an intensive 2-day Fibromyalgia Treatment Program at a tertiary medical center in the United States after FM diagnosis. Patients were administered the Fibromyalgia Impact Questionnaire–Revised, the Center for Epidemiologic Study of Depression Scale, and the Pain Catastrophizing Scale upon admission to the program. Demographic information and opioid use were self-reported. Logistic regression analysis was utilized to determine associations between patient-related variables and opioid use in this prospective study. Results Of 698 patients, 27.1% (n = 189) were taking opioids at intake. Extended duration of symptoms (>3 years), increased age, higher degree of functional impairment, and increased pain catastrophizing were significantly associated with opioid use. Conclusions Opioids are not recommended for the treatment of FM under current guidelines. Greater burden of illness appeared to be associated with the prescription and use of opioids in this population. These findings suggest that some providers may not be aware of current recommendations that have been found to be effective in the management of FM that are contained in guidelines. Alternative approaches to the management of FM that do not involve opioids are reviewed in an effort to improve care.
Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I
Peck, Dawn , Lacey, Jean M., White, Amy , Pino, Gisele , Studinski, April, Fisher, Rachel , Ahmad, Ayesha , Viall, Sarah , Shallow, Natalie, Siemon, Amy, Hamm, J. Austin, Murray, Brianna K., Jones, Kelly L. , Gavrilov, Dimitar , Oglesbee, Devin , Raymond, Kimiyo , Matern, Dietrich , Rinaldo, Piero, Tortorelli, Silvia , Price, Theodore J. , Peck, Dawn S, White, Amy L , Studinski, April L, Jones, Kelly L , Oglesbee, Devin , Price, Theodore J , Spencer, Linda J. , Murray, Brianna K.

Mayo Clinic

International Journal of Neonatal Screening | February 7, 2020 | Volume: 6 | Issue: 1 | Pages: 10

10.3390/ijns6010010 | PMID 33073008 Get It

Enzyme-based newborn screening for Mucopolysaccharidosis type I (MPS I) has a high false-positive rate due to the prevalence of pseudodeficiency alleles, often resulting in unnecessary and costly follow up. The glycosaminoglycans (GAGs), dermatan sulfate (DS) and heparan sulfate (HS) are both substrates for α-l-iduronidase (IDUA). These GAGs are elevated in patients with MPS I and have been shown to be promising biomarkers for both primary and second-tier testing. Since February 2016, we have measured DS and HS in 1213 specimens submitted on infants at risk for MPS I based on newborn screening. Molecular correlation was available for 157 of the tested cases. Samples from infants with MPS I confirmed by IDUA molecular analysis all had significantly elevated levels of DS and HS compared to those with confirmed pseudodeficiency and/or heterozygosity. Analysis of our testing population and correlation with molecular results identified few discrepant outcomes and uncovered no evidence of false-negative cases. We have demonstrated that blood spot GAGs analysis accurately discriminates between patients with confirmed MPS I and false-positive cases due to pseudodeficiency or heterozygosity and increases the specificity of newborn screening for MPS I.
Commentary on Cryptogenic Cushing Syndrome Due to a White Lie
Grebe, Stefan K. , Grebe, Stefan K G

Mayo Clinic

Clinical Chemistry | February 6, 2020 | Volume: 66 | Issue: 5 | Pages: 662-663

10.1093/clinchem/hvaa037 | PMID 32353134 Get It

An Investigation of Healthcare Worker Perception of Their Workplace Safety and Incidence of Injury
Aljabri, Duaa , Vaughn, Andrew I. S., Austin, Matthew, White, Launia J. , Li, Zhuo , Naessens, James M. , Spaulding, Aaron , Li, Zhuo , Vaughn, Andrew, White, Launia, Naessens, James , Spaulding, Aaron

Mayo Clinic

Workplace Health & Safety | January 26, 2020 | Volume: 68 | Issue: 5 | Pages: 214-225

10.1177/2165079919883293 | PMID 31983297 Get It

Background: Managing the safety climate in health care is a promising tool for improving employee and patient safety in the health care work environment. Gaps in the theoretical and conceptual underpinnings of safety climate, as well as the evidence base for its practical application in health care remain. The purpose of this study was to evaluate the number of work injuries occurring in health care work units and associated safety climate beliefs. Methods: A retrospective analysis was conducted utilizing organizational staff survey data collected by a large medical hospital in the Midwest in 2015. Employees ( n = 32,327) were invited to identify safety climate perceptions via survey. Injuries, days restricted, and days absent were identified through the Hospital’s Occupational Safety and Health Administration (OSHA) log. Zero inflated negative binomial regressions used injuries as dependent variables and safety climate perceptions as independent variables. Findings: In all, 23,599 employees completed the survey (73% response rate) across 1,805 employee work units which were defined as groupings of employees reporting to a single supervisor. We found that there was an association between fewer injuries and health care workers indicating that they share responsibility for compliance with safety rules and procedures (relative risk [RR] = 0.98, 95% confidence interval [CI] = [0.98, 0.99]). Conclusion/Application to Practice: This study supports the use of a safety climate measure to assess working units’ perceptions of employee safety. A continued focus on the health and safety of employees who interact directly with patients is warranted, as well as employees who do not provide direct patient care.
Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer
Parsons, J. Kellogg , Zahrieh, David , Mohler, James L. , Hansel, Donna E. , Kibel, Adam S. , Liu, Heshan , Seisler, Drew K., White, Martha M. , Hahn, Olwen, Hartman, Sheri J. , Stroup, Sean P. , Veldhuizen, Peter J. Van , Hall, Lannis, Pierce, John P. , Marshall, James R. , Paskett, Electra D. , Natarajan, Loki , Taylor, John, Small, Eric J. , Morris, Michael J.

Mayo Clinic

JAMA | January 14, 2020 | Volume: 323 | Issue: 2 | Pages: 140

10.1001/jama.2019.20207 | PMID 31935026 Get It

Menopausal hormone therapy, blood thrombogenicity, and development of white matter hyperintensities in women of the Kronos Early Estrogen Prevention Study
Jayachandran, Muthuvel , Lahr, Brian D. , Bailey, Kent R. , Miller, Virginia M. , Kantarci, Kejal , Kantarci, Kejal

Mayo Clinic

Menopause | January 14, 2020 | Volume: 27 | Issue: 3 | Pages: 305-310

10.1097/gme.0000000000001465 | PMID 31934946 Get It

Abstract Objective: Development of white matter hyperintensities (WMH) in the brain is associated with blood thrombogenicity in recently menopausal women. This study examined the influence of menopausal hormone treatments (MHTs) on this association. Methods: Measures of blood thrombogenicity were examined in women of the Kronos Early Estrogen Prevention Study (n = 95) who had brain magnetic resonance imaging before and during the 48 months of randomization to transdermal 17β-estradiol (n = 30), oral conjugated equine estrogen (n = 29) both with progesterone for 12 days per month or placebo pills and patch (n = 36). Principal components (PCs) analysis was used to reduce the dimensionality of 14 markers of platelet activation and blood thrombogenicity. The first 5 PCs were assessed for association with treatment and changes in WMH. Within-person slopes were obtained to capture the extent of WMH change for each woman. Results: WMH increased in all groups over the 48 months (P = 0.044). The partial effect of PC1, representing an average of six thrombogenicity variables (microvesicles derived from endothelium, leukocytes, and monocytes, and positive for tissue factor and adhesion molecules) on WMH was significant (P = 0.003). PC3, reflecting a contrast of platelet microaggregates and adenosine triphosphate secretion versus total platelet count, differed across groups (P = 0.006) with higher scores in the oral conjugated equine estrogen group. The global association between PCs and WMH increase, however, did not differ significantly by MHT (P = 0.207 for interaction between MHT and PC's). Conclusion: In recently menopausal women, the type of MHT did not significantly influence the association of markers of blood thrombogenicity with development of WMH in the brain.
Amphetamine–Dextroamphetamine and Pregnancy: Neonatal Outcomes After Prenatal Prescription Mixed Amphetamine Exposure
Rose, Sherrill, Hathcock, Matthew , Borowski, Kristi, Rivera‐Chiauzzi, Enid Y. , Rose, Sherrill J, Hathcock, Matthew A, White, Wendy M, Rivera-Chiauzzi, Enid Y , White, Wendy

Mayo Clinic

Journal of Attention Disorders | January 13, 2020 | Volume: 25 | Issue: 9 | Pages: 1295-1301

10.1177/1087054719896857 | PMID 31931669 Get It

Objective: A retrospective cohort study was performed to evaluate whether birthweight was less among infants of women taking amphetamine–dextroamphetamine during pregnancy at our academic institution. Method: We identified mother–infant pairs with documented exposure to amphetamine–dextroamphetamine in pregnancy from 2005 through 2015. Patients were matched 2:1 with unexposed controls. Charts were reviewed for known causes of intrauterine growth restriction. Analysis of birthweight used generalized estimating equation blocking on matching. Medical histories were analyzed with χ 2 test or Fisher’s exact test. Results: We identified 53 exposed mother–infant pairs. The difference in mean birthweight of infants exposed to amphetamine–dextroamphetamine versus those not exposed was 26.9 g, which is not significant (95% confidence interval [CI] = [−141, 195 g]; p = .75). A significant difference was noted for exposed versus unexposed mothers for comorbid psychiatric illness and history of substance abuse ( p < .001). Conclusion: With a limited sample size, our study suggests no significant difference in birthweight.
A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer
Zhong, Jun, Jermusyk, Ashley , Wu, Lang , Hoskins, Jason W. , Collins, Irene , Mocci, Evelina , Song, Lei , Chung, Charles C., Xiao, Wenming , Andreotti, Gabriella , Arslan, Alan A. , Babić, Ana , Berndt, Sonja, Borgida, Ayelet , Bracci, Paige M. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Childs, Erica J., Du, Mengmeng , Fuchs, Charles S. , Gallinger, Steven , Gaziano, J. Michael, Giovannucci, Edward L. , Goodman, Gary E. , Goodman, Phyllis J. , Haiman, Christopher, Hartge, Patricia, Hasan, Manal , Helzlsouer, Kathy J., Holly, Elizabeth A., Klein, Eric A. , Kogevinas, Manolis, Kurtz, Robert J., Ng, Kimmie , Obazee, Ofure , Oberg, Ann L. , Patel, Alpa V. , Peters, Ulrike , Porta, Miquel , Rothman, Nathaniel , Scélo, Ghislaine , Sesso, Howard D. , Sieri, Sabina , Tjønneland, Anne , Thornquist, Mark, Trichopoulou, Antonia , Visvanathan, Kala , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Yuan, Chen , Zeleniuch‐Jacquotte, Anne , Hoover, Robert N. , Brown, Kevin M. , Jacobs, Eric J. , Li, Donghui , Yu, Kai , Wolpin, Brian M. , Chatterjee, Nilanjan , Shi, Jianxin , Petersen, Gloria M. , Zhong, Jun , Arslan, Alan A , Tjønneland, Anne , Wactawski-Wende, Jean , Visvanathan, Kala , Klein, Eric A , Porta, Miquel , Zeleniuch-Jacquotte, Anne , Zhong, Jun , Yuan, Chen , Hoskins, Jason W , Zhang, Mingfeng , Zhang, Tongwu , Albanes, Demetrius , Bamlet, William R. , Freeman, Laura E. Beane , Brais, Lauren K , Canzian, Federico , Cotterchio, Michelle , Duell, Eric J. , Giles, Graham G. , Goggins, Michael , Marchand, Loı̈c Le , Malats, Núria , Männistö, Satu , Milne, Roger L. , Neale, Rachel Ε. , Orlow, Irene , Rothman, Nathaniel , Severi, Gianluca , Silverman, Debra T. , Sund, Malin , Tobias, Geoffrey S. , Van Den Eeden, Stephen K , White, Emily , Yu, Kai , Kooperberg, Charles , Risch, Harvey A. , Shu, Xiao‐Ou , Chanock, Stephen Jacob , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Smith, Jill Palmer , Kraft, Peter , Zheng, Wei , Ámundadóttir, Laufey T.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | December 31, 2019 | Volume: 112 | Issue: 10 | Pages: 1003-1012

10.1093/jnci/djz246 | PMID 31917448 Get It

Abstract Background Although 20 pancreatic cancer susceptibility loci have been identified through genome-wide association studies in individuals of European ancestry, much of its heritability remains unexplained and the genes responsible largely unknown. Methods To discover novel pancreatic cancer risk loci and possible causal genes, we performed a pancreatic cancer transcriptome-wide association study in Europeans using three approaches: FUSION, MetaXcan, and Summary-MulTiXcan. We integrated genome-wide association studies summary statistics from 9040 pancreatic cancer cases and 12 496 controls, with gene expression prediction models built using transcriptome data from histologically normal pancreatic tissue samples (NCI Laboratory of Translational Genomics [n = 95] and Genotype-Tissue Expression v7 [n = 174] datasets) and data from 48 different tissues (Genotype-Tissue Expression v7, n = 74–421 samples). Results We identified 25 genes whose genetically predicted expression was statistically significantly associated with pancreatic cancer risk (false discovery rate &lt; .05), including 14 candidate genes at 11 novel loci (1p36.12: CELA3B; 9q31.1: SMC2, SMC2-AS1; 10q23.31: RP11-80H5.9; 12q13.13: SMUG1; 14q32.33: BTBD6; 15q23: HEXA; 15q26.1: RCCD1; 17q12: PNMT, CDK12, PGAP3; 17q22: SUPT4H1; 18q11.22: RP11-888D10.3; and 19p13.11: PGPEP1) and 11 at six known risk loci (5p15.33: TERT, CLPTM1L, ZDHHC11B; 7p14.1: INHBA; 9q34.2: ABO; 13q12.2: PDX1; 13q22.1: KLF5; and 16q23.1: WDR59, CFDP1, BCAR1, TMEM170A). The association for 12 of these genes (CELA3B, SMC2, and PNMT at novel risk loci and TERT, CLPTM1L, INHBA, ABO, PDX1, KLF5, WDR59, CFDP1, and BCAR1 at known loci) remained statistically significant after Bonferroni correction. Conclusions By integrating gene expression and genotype data, we identified novel pancreatic cancer risk loci and candidate functional genes that warrant further investigation.